Galectin Therapeutics Appoints Joel Lewis as Chief Executive Officer

Norcross, GA, September 2 2020 (Globe Newswire) — Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of current board member, Joel Lewis, to the position of Chief Executive Officer (CEO) and President.

What do you think?

Written by hsandm

Danaher Appoints Rainer M. Blair as President and CEO

CM Life Sciences, Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsized $385 Million Initial Public Offering